Navigation Links
Transave Issued Key Composition of Matter Patent for ARIKACE™
Date:5/24/2010

MONMOUTH JUNCTION, N.J., May 24 /PRNewswire/ -- Transave Inc. today announced that the United States Patent and Trademark Office has issued an important composition of matter patent (U.S. Patent No. 7,718,189) for liposomal aminoglycoside formulations including its lead compound, ARIKACE™ (liposomal amikacin for inhalation). The company expects that the patent will provide exclusivity for ARIKACE until October 1, 2026.

"The issuance of this composition of matter patent significantly strengthens the intellectual property estate around ARIKACE and represents a valuable asset for Transave," said Tim Whitten, Transave's chief executive officer.  "We are continuing to secure and expand our proprietary position for ARIKACE which has the potential to become an important treatment for cystic fibrosis (CF) patients with Pseudomonas lung infections, non-CF bronchiectasis patients with Pseudomonas lung infections, and patients with nontuberculous mycobacteria (NTM) lung infections. We look forward to moving to Phase 3 as soon as possible."

The company also announced that the U.S. Patent office granted another patent (U.S. Patent No. 7,544,369) last year covering ARIKACE for the sustained release of antibiotic and once-daily treatment of Pseudomonas lung infections.

About ARIKACE™

ARIKACE is a form of the antibiotic amikacin, which is enclosed in nanocapsules of lipid called liposomes. This advanced pulmonary liposome technology prolongs the release of amikacin in the lungs while minimizing systemic exposure.  The treatment uses biocompatible lipids endogenous to the lung that are formulated into small (0.3 micron), neutral liposomes th
'/>"/>

SOURCE Transave, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria
2. Transave, Inc. Secures $12.5 Million in New Financing
3. Transave, Inc. Raises $35 Million Through Series D Convertible Preferred Stock Financing
4. Details Issued Today on $1 Billion in Biotech Tax Credits and Grants
5. Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate
6. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
7. Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
8. Arobella Medical CEO is Issued U.S. Patent for Ultrasound Wound Therapy Technology
9. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
10. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
11. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 OTC ... Pharmaceuticals Inc., a biotechnology company, on its approval ... previously traded on OTCQX®, the best marketplace for ... Markets Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... the successful execution of its growth strategy and ...
(Date:8/21/2014)... 21, 2014 Ontotext S4 , ... Ontotext . Now the same enterprise hardened ... structured and unstructured data is available to start-ups and ... enterprise technology. Organizations that do not have resources to ... can use S4 since there is no need for ...
(Date:8/20/2014)... 2014 Clintrax Global, Inc., a worldwide ... Raleigh, NC , recently announced the ... President of Administration. As Vice ... processes, including their alignment with company objectives and ... as an HR executive, specializing in needs assessments, ...
(Date:8/20/2014)... Aug. 20, 2014 Neurotrope, Inc. (OTCQB: ... conference call to provide an update on Company ... daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) or ... cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference replay ... through September 2, 2014 at (888) 203-1112 (U.S. ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4Clintrax Global, Inc. Announces Addition to Executive Team 2Neurotrope To Host Conference Call 2
... Jan. 9, 2012 Reportlinker.com announces ... is available in its catalogue: , ... Transplantation, Cord Blood Banking and Drug ... There is great interest ...
... Sequenom, Inc. (NASDAQ: SQNM ), a life ... of the Company,s 2011 performance and accomplishments, as well as ... Initial 2011 Performance Results ... for 2011 (unaudited). , Over 21,000 total prenatal and ...
... today that it has secured $47.5 million in Series ... financing along with existing investors OrbiMed Advisors, New Enterprise ... financing, Josh Bilenker, M.D., Partner at Aisling Capital, will ... round will support commercialization of the company,s Atlas™ System ...
Cached Biology Technology:Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 2Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 3Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 4Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 5Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 6Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 2Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 3Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 4Roka Bioscience Secures $47.5 Million in Series D Financing 2
(Date:8/20/2014)... from the University of Tbingen, Arizona State University, the ... Public Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... least 1000 years old. The pathogen is a relative ... occasionally causes disease in humans today. These researchers assume ... Peruvian coast. "The link to sea lions was unexpected" ...
(Date:8/20/2014)... that acral melanomas the rare type of skin cancer ... distinct from other more common types of skin cancer, according ... Pigment Cell & Melanoma Research . , Acral melanoma ... the feet, nail-beds and other hairless parts of the skin. ... by UV damage from the sun. , The team, from ...
(Date:8/20/2014)... and plastic bags could one day be made out ... scientists are now reporting. The novel process they developed ... with its agricultural and plastic waste problems, appear in ... Ilker S. Bayer and colleagues at the Italian Institute ... growing. In 2012, its production reached 288 million tons ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2
... , Cincinnati, (OH) - The International Rett Syndrome Foundation (IRSF) ... 18 new grants designed to study a variety of diverse ... and outcome measures for Rett syndrome. IRSF is the ... Rett syndrome research with the cumulative total of research spending ...
... German-based project is setting out to rescue biodiversity data at ... institutional databases, are kept in outdated digital storage systems, or ... Botanic Garden and Botanical Museum Berlin-Dahlem, provides a good example ... data. This is one of a set of data ...
... that is associated with the spread of cancer has won ... one of this year,s Kaye Innovation Awards at the university. ... of Prof. Chaim Gilon and Prof. Alexander Levitzki at the ... B (PKB, also called Akt). Since the activation of PKB ...
Cached Biology News:IRSF awards over $1.5 million for basic and translational research for Rett syndrome 2IRSF awards over $1.5 million for basic and translational research for Rett syndrome 3German research team targets 'at risk' data on biodiversity 2German research team targets 'at risk' data on biodiversity 3